# Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

> **NCT00335764** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 92 (actual)

## Conditions studied

- Adult Giant Cell Glioblastoma
- Adult Glioblastoma
- Adult Gliosarcoma
- Recurrent Adult Brain Tumor

## Interventions

- **DRUG:** sorafenib tosylate
- **DRUG:** erlotinib hydrochloride
- **DRUG:** tipifarnib
- **DRUG:** temsirolimus

## Key facts

- **NCT ID:** NCT00335764
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-04
- **Primary completion:** 2010-02
- **Final completion:** 2012-09
- **Target enrollment:** 92 (ACTUAL)
- **Last updated:** 2018-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00335764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00335764, "Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00335764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*